Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 8,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Terminated Not applicable Interventional Results available

First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness

NCT04485858
View directory record Official record
Conditions
Corneal Disease, Corneal Opacity, Corneal Injuries
Interventions
CorNeat KPro
Device
Lead sponsor
CorNeat Vision Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 30, 2026, 9:44 PM EDT
Terminated Phase 3 Interventional Results available

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

NCT01905592
View directory record Official record
Conditions
Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Neoplasms
Interventions
niraparib, Physician's choice
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 30, 2026, 9:44 PM EDT
Terminated Not applicable Interventional Results available

Furosemide vs Placebo for Brain Relaxation

NCT01054404
View directory record Official record
Conditions
Brain Swelling, Brain Edema, Dehydration
Interventions
Furosemide, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 30, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer

NCT01716195
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Induction Chemotherapy followed by Response Adapted Chemoradiation
Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 30, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Antacids on the Pharmacokinetics of Raltegravir

NCT00944307
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir, antacid
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 30, 2026, 9:44 PM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00074971
View directory record Official record
Conditions
Fabry Disease
Interventions
Fabrazyme (agalsidase beta)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
16 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 30, 2026, 9:44 PM EDT
Terminated No phase listed Observational

Structural Analysis of Human Tissue

NCT01293864
View directory record Official record
Conditions
Cutis Laxa
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 9:44 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

HCV Test and Treat Utilizing Simplified HCV Patient Education

NCT05582681
View directory record Official record
Conditions
Hepatitis C
Interventions
Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir
Diagnostic Test · Other · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Long Island City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 30, 2026, 9:44 PM EDT
Completed Phase 1 Interventional

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

NCT04572100
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Transoral Robotic Surgery (TORS) or Radiotherapy, Chemotherapy and Low-Dose Radiotherapy, Chemotherapy and High-Dose Radiotherapy, Paclitaxel, Carboplatin
Other · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 30, 2026, 9:44 PM EDT
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 30, 2026, 9:44 PM EDT
Terminated No phase listed Observational Results available

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection

NCT01182298
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 30, 2026, 9:44 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Andecaliximab, Placebo
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
2 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Results available

Continuous Infusion of rhIL-15 for Adults With Advanced Cancer

NCT01572493
View directory record Official record
Conditions
Lymphoma, Carcinoma
Interventions
rh IL-15 (10 DAYS), rh IL-15 (5 DAYS)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 30, 2026, 9:44 PM EDT
Completed No phase listed Observational Results available

Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza

NCT01769430
View directory record Official record
Conditions
Influenza Virus Infection Transmission in Humans
Interventions
Observational Study of influenza aerosol shedding -- No Intervention
Other
Lead sponsor
University of Maryland, College Park
Other
Eligibility
10 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 30, 2026, 9:44 PM EDT
Completed Phase 3 Interventional

A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP

NCT00000700
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
28
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 30, 2026, 9:44 PM EDT
Completed No phase listed Observational

A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir

NCT02103699
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
No intervention
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 30, 2026, 9:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Human Epididymis Protein 4 in Normal Menstruating Women

NCT01337999
View directory record Official record
Conditions
Healthy Premenopausal Women
Interventions
blood draws
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 30, 2026, 9:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

Muscle Fiber Fragment Treatment for Urinary Incontinence

NCT01953263
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Autologous Muscle Fiber Fragments
Other
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 9:44 PM EDT
Terminated Phase 2 Interventional Results available

An Extension of Protocol PRO 140_CD01 Study

NCT02355184
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
PRO 140 350mg weekly subcutaneous (SC) injection.
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 30, 2026, 9:44 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study of Human Tear Proteins

NCT00453258
View directory record Official record
Conditions
Eye Disease
Interventions
Eye Examination
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 30, 2026, 9:44 PM EDT
Completed No phase listed Observational

Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors

NCT00819026
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 30, 2026, 9:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

NCT02057263
View directory record Official record
Conditions
Hepatitis B
Interventions
Alendronate, Hepatitis B Vaccine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 30, 2026, 9:44 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Regional Fatty Acid Metabolism in Humans

NCT00068887
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 30, 2026, 9:44 PM EDT
Active, not recruiting Early Phase 1 Interventional

Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

NCT04528004
View directory record Official record
Conditions
Heart Failure, Systolic, Heart Failure NYHA Class IV, Metabolic Disturbance
Interventions
Nicotinamide riboside, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 30, 2026, 9:44 PM EDT